<DOC>
	<DOCNO>NCT00924547</DOCNO>
	<brief_summary>Oral supplementation patient affect cystic fibrosis docosahexanoic acid ( DHA ) result normalization know fatty acid derangement patient diminish production proinflammatory isoprostanes 8-isoprostane-PGF2Î± .</brief_summary>
	<brief_title>Oral Docosahexanoic Acid Supplementation Cystic Fibrosis</brief_title>
	<detailed_description>The study design single-center , randomize , placebo-controlled , cross-over trial . After informed consent obtain , 18 eligible subject pancreatic insufficient cystic fibrosis enrol study . Participants take part two 4 week study session , separate 4 week washout period . One session involve treatment placebo two session provide treatment approximately 25mg 35 mg DHA/kg body weight . The patient assign treatment session random order , describe . The DHA source provide Martek Biosciences Corporation , Columbia , MD , USA form chewable capsule contain 200 mg DHA . The placebos identical DHA supplement contain active ingredient , DHA . Subjects instruct take study capsule addition normal dos pancreatic enzyme meal maintain usual diet . Blood , urine , exhale breath condensate sample collect baseline completion study period . Patients screen enrolled present clinic routine check-up . The subject routine blood work annual check-ups , possible additional tube blood save baseline fatty acid profile avoid unnecessary blood draw . Following study period , blood draw , urine collection , exhale breath condensate ( EBC ) collect Vanderbilt Clinical Research Center . The patient also give supply DHA placebo ( entire study ) time enrollment . The order take supplement placebo determine use randomization table .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Diagnosis Cystic Fibrosis base sweat chloride value &gt; 60 mEq/L genotyping Pancreatic insufficiency , define requirement treatment exogenous pancreatic enzyme FEV 1 &gt; 40 Less 3 pulmonary exacerbation last year ( diagnosed pulmonary attend physician ) Age great 6 year Capability perform pulmonary function test Ability swallow gel capsule Ability comply medication use , study visit , study procedure Written inform consent obtain subject study subject 's legal representative Presence severe CFrelated liver disease , include SGOT SGPT &gt; 3 time normal limit , history biliary cirrhosis , portal hypertension Severe pulmonary disease , define FEV1 &lt; 40 % Elevated serum creatinine BUN Pregnancy PT &gt; 1.5 time normal Diabetes mellitus Daily use NSAIDs anticoagulant History fish allergy Use ticlopidine , clopidogrel , dipyridamole Use glucocorticoids History lung transplant currently lung transplantation list Presence condition abnormality opinion investigator would compromise safety subject quality data</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Docosahexanoic Acid</keyword>
	<keyword>DHA</keyword>
	<keyword>isoprostanes</keyword>
	<keyword>fatty acid</keyword>
</DOC>